RT Journal Article
SR Electronic
T1 O04.2 Hormonal Contraception is Associated with a Reduced Risk of Bacterial Vaginosis: A Systematic Review and Meta-Analysis
JF Sexually Transmitted Infections
JO Sex Transm Infect
FD BMJ Publishing Group Ltd
SP A32
OP A33
DO 10.1136/sextrans-2013-051184.0102
VO 89
IS Suppl 1
A1 L A Vodstrcil
A1 J S Hocking
A1 M Law
A1 S Walker
A1 C K Fairley
A1 S Tabrizi
A1 C S Bradshaw
YR 2013
UL http://sti.bmj.com/content/89/Suppl_1/A32.3.abstract
AB Background We conducted a systematic review and meta-analysis of published data to examine the association between hormonal contraception (HC) and bacterial vaginosis (BV). Methods Three databases (Medline, Web of Science and Embase) were searched until the end of January 2013 and duplicate references removed. Inclusion criteria were (1) > 20 BV cases; (2) data available to derive the association between HC and BV; (3) > 10% of participants used HC; (4) accepted BV diagnostic method. Data extracted included: type of HC, BV diagnostic method, and BV outcome (prevalent, incident, recurrent). Meta-analyses were conducted to calculate overall and pooled odds/risk ratios (OR/RR), stratified by HC-type and BV outcome. This systematic review is registered with PROSPERO (CRD42013003699). Results Of 1710 unique references identified, 328 were assessed for eligibility and 48 studies met inclusion criteria. Overall, 36 reported BV-prevalence, 12 BV-incidence and 3 BV-recurrence. Twenty three studies reported data for combined-HC, 9 for progesterone-only HC and 23 did not specify HC-type. Diagnostic methods included: Nugent’s (n = 31), Amsel’s (n = 15), Spiegel’s (n = 1) and Ison-Hay (n = 1). Pooled BV prevalence was 30.7% (95% CI: 26.7–34.7%) and ranged from 4.7%–66.7%, with > 99% of the observed variance of prevalent BV explained by heterogeneity (I2 = 99.6%). The pooled effect of any HC-use on the composite-BV outcome (prevalent/incident/recurrent) was OR = 0.67 (95% CI: 0.62–0.71). When stratified by BV outcome, any HC-use was associated with decreased risk of prevalent (OR = 0.63; 0.58–0.68), incident (RR = 0.78; 0.68–0.87) and recurrent (RR = 0.61; 0.49–0.73) BV. When prevalent BV was stratified by HC-type, combined-HC (OR = 0.68; 0.62–0.74), unspecified HC-type (OR = 0.60; 0.53–0.67), and progesterone-only methods (OR = 0.67; 0.46–0.88) were all associated with decreased risk of prevalent BV. Conclusion HC-use is associated with a significant and consistent decreased risk of all BV outcomes, with a greater reduction in risk for prevalent than incident BV. Surprisingly, both combined and progesterone-only contraceptive methods were associated with reduced risk of prevalent BV.